Story thread · 2 reports / 2 sources
First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC
medscape.com · 18h · first report
DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival. Medscape Medical News
The coverage
- The Age of Mutant Plants
cascadepbs.org · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.